AmerisourceBergen Acquires PharmaLex for $1.28 Billion

AmerisourceBergen Corp. (ABC), a drug wholesaler, has signed a definitive agreement to acquire PharmaLex Holding GmbH, a specialized services source for the pharma, biotech, and medtech industries, for $1.28 billion in cash. The deal boosts ABC’s portfolio to support manufacturer partners across the pharma development and commercialization journey. The deal is expected to close by March 2023.

PharmaLex features a staff of scientific, regulatory, and safety and compliance (GxP) experts that offer strategic guidance and regulatory support to biopharma companies throughout a product’s lifecycle. The company provides tech-enabled services ranging from clinical development consulting to marketing authorization, enabling clients to efficiently bring products to global markets and diverse patient populations.

“ … AmerisourceBergen is committed to building on our leadership in specialty services through a continued focus on innovation and partnerships, and by acquiring PharmaLex, we will be able to further enhance our value proposition to pharmaceutical manufacturers, from emerging biotechs to global biopharmaceutical leaders,” says Steven H. Collis, chairman, president, and CEO of ABC. “PharmaLex’s highly complementary business and strong market reputation will deepen our partnerships with manufacturers, advancing our role as a strategic partner of choice as we support end-to-end clinical and commercial enablement solutions for our pharma customers. We look forward to welcoming the PharmaLex team to create healthier futures with AmerisourceBergen.”